Y

ou, the readers of STAT, have spoken. Your votes determined the best and worst biopharma CEOs of 2017.

The Best: John Maraganore of Alnylam Pharmaceuticals. Congratulations, John!

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi, Adam. I have followed STAT’s reports on Dr. Soon-Shiong. As a former journalist, I am appalled that he has just bought the LA Times. The horse is probably out of the barn on that sale. But I’m wondering if you guys are planning to circle back and update the tale of his health care boondoggles….

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy